Synthetic Biologics Inc. (SYN)
$0.70
$-0.02
(-2.78%)
As on 05-Dec-2022 09:30EDT
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-15 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
15,844,100
10 Years Aggregate
CFO
$-175.92 Mln
EBITDA
$-212.89 Mln
Net Profit
$-188.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Synthetic Biologics (SYN)
| -74.3 | -3.1 | -51.4 | -77.4 | -44.9 | -68.4 | -49.6 |
|
BSE Sensex*
| -11.8 | -2.9 | -8.2 | -8.4 | 6.1 | 7.5 | 10.8 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Synthetic Biologics (SYN)
| -29.5 | -24.4 | -9.5 | -96.8 | -33.4 | -66.7 | 56.8 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Synthetic Biologics (SYN)
|
0.7 | 16.2 | 0.0 | -19.4 | -- | -30.7 | -- | 0.2 |
| 70.8 | 10,974.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.1 | |
| 71.6 | 10,421.8 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 49.0 | 12,688.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.7 | 6.5 | |
| 128.1 | 17,196.9 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 66.2 | 7,892.5 | 1,508.5 | 348.8 | 57.0 | 96.4 | 23.3 | 35.9 | |
| 291.0 | 9,110.1 | 417.3 | 225.0 | 42.8 | 18.6 | 41.4 | 7.1 | |
| 465.5 | 11,464.9 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.4 | |
| 440.5 | 12,769.3 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.2 | 20.4 | |
| 284.0 | 9,756.7 | 0.0 | -326.5 | -- | -37.2 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Synthetic Biologics (SYN)
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam... antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. Read more
-
CEO, CFO, Treasurer, Corp. Sec. & Director
Mr. Steven A. Shallcross CPA
-
Chief Operating Officer
Dr. Frank Tufaro Ph.D.
-
Headquarters
Rockville, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Synthetic Biologics (SYN)
What is the current share price of Synthetic Biologics Inc (SYN) Today?
The share price of Synthetic Biologics Inc (SYN) is $0.70 (NYSE) as of 05-Dec-2022 09:30 EDT. Synthetic Biologics Inc (SYN) has given a return of -44.88% in the last 3 years.
What is the current PB & PE ratio of Synthetic Biologics Inc (SYN)?
Since, TTM earnings of Synthetic Biologics Inc (SYN) is negative, P/E ratio is not available.
The P/B ratio of Synthetic Biologics Inc (SYN) is 0.24 times as on 05-Dec-2022, a 95 discount to its peers’ median range of 4.44 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Synthetic Biologics Inc (SYN)?
The 52-week high and low of Synthetic Biologics Inc (SYN) are Rs -- and Rs -- as of 02-Jun-2026.
What is the market cap of Synthetic Biologics Inc (SYN)?
Synthetic Biologics Inc (SYN) has a market capitalisation of $ 16 Mln as on 05-Dec-2022. As per SEBI classification, it is a company.
Should I invest in Synthetic Biologics Inc (SYN)?
Before investing in Synthetic Biologics Inc (SYN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.